Precision immunodiagnostic and immunotherapy firm Navidea Biopharmaceuticals named Michael Rosol, Ph.D., to be its new chief medical officer, effective Dec. 17.
Rosol most recently served as an associate director in the clinical and translational imaging group at the Novartis Institutes for BioMedical Research.
“We are pleased for Dr. Rosol to join Navidea and bring his deep insights into the needs of the industry for the development, validation and implementation of imaging biomarkers in clinical trials,” said Navidea CEO Jed Latkin in a statement.
“He brings a wealth of knowledge and extensive experience to Navidea as we move forward with advancing our novel pipeline of imaging products and bringing products to market,” Latkin said.
Before NIBR, he was a senior director of business development at Elucid Bioimaging, where he helped commercialize its computer-aided phenotyping applications. Prior to that, he served as chief scientific officer of MediLumine. Rosol also headed up Novartis Pharmaceuticals’ translational imaging group.
RELATED: Slew of SEC filings show up widening cracks at Navidea
The Dublin, Ohio-based Navidea hit a rough patch in mid-2016, which saw the departure of board directors and the company’s accounting firm.
Amid a series of SEC filings, the company said it was delaying the reporting of quarterly financial results while it weathered claims from a Houston investment firm that it defaulted on a $60 million loan.
Navidea would later sell its cancer diagnostic radioimaging agent Lymphoseek to Cardinal Health in a deal worth up to $310 million, along with the rights to all approved, pending and future oncology applications.